Molecule of the Week


April 13, 2009

Since 1997, finasteride has been marketed under many trade names (Propecia is the most prominent) for reversing the effects of male pattern hair loss. But before that—in 1992—it was approved by the US Food and Drug Administration for treating benign prostatic hyperplasia (enlarged prostate gland) and prostate cancer. In 2008, the Swedish Medical Academy advised users that finasteride may have persistent sexual side effects.